EU expands approval of Servier's Procoralan to include use with beta blockers
This article was originally published in Scrip
Executive Summary
The European Commission has approved Servier's Procoralan (ivabradine) for use with beta-blockers in chronic stable angina patients who are inadequately controlled on beta-blockers and who have heart rates above 60 beats per minute. The I(f) channel (a potassium/sodium channel) agonist was already approved for the treatment of chronic stable angina pectoris in patients who are unsuitable for beta-blocker therapy.